Welcome to our dedicated page for Neurogene SEC filings (Ticker: NGNE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Neurogene's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Neurogene's regulatory disclosures and financial reporting.
Neurogene Inc. President and CFO Christine Mikail Cvijic reported open-market sales of 4,800 shares of common stock under a pre-arranged Rule 10b5-1 trading plan. The sales occurred on two days at weighted average prices around the mid-$36 range.
After these transactions, she reports ownership of 84,040 shares, which includes 10,635 restricted stock units scheduled to vest on March 13, 2027, 13,533 restricted stock units vesting in equal installments on March 26, 2027 and March 26, 2028, and 22,000 restricted stock units vesting annually from February 20, 2027 through February 20, 2029. The filing notes that following completion of these sales she no longer holds any shares jointly with her spouse.
Neurogene Inc. director and President/CFO Christine Mikail Cvijic reported open-market sales of 4,800 shares of common stock. The sales occurred on July 1–2, 2026 in three tranches at weighted average prices around $34–$35 per share.
The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 18, 2025, and involved shares held jointly with her spouse. Following these sales, she continues to directly hold 88,840 shares, along with additional unvested restricted stock units scheduled to vest between 2027 and 2029.
Neurogene Inc. entered into an underwriting agreement to complete a public offering of its common stock and pre-funded warrants. The company is issuing 3,500,000 shares of common stock at $30.00 per share and pre-funded warrants to purchase up to 666,666 shares at $29.999999 each. Underwriters exercised in full a 30‑day option to buy an additional 624,999 shares at the public offering price, less underwriting discounts and commissions. Net proceeds from the offering, including the exercised option, are expected to be approximately $134.8 million after fees and expenses. The company states that these proceeds, together with existing cash and cash equivalents, should fund operating and capital needs into the first quarter of 2029.
Neurogene Inc. is offering 3,500,000 shares of common stock and, in lieu of shares to certain investors, pre-funded warrants to purchase 666,666 shares. The public offering price is $30.00 per share. Net proceeds are expected to be approximately $117.2 million (or $134.8 million if the underwriters’ option is exercised in full). Delivery is expected on or about July 2, 2026. The prospectus supplement states the company intends to use proceeds to fund clinical development and pre-commercial activities for NGN-401, for working capital and general corporate purposes. Total common shares outstanding immediately after the offering are projected to be 19,115,786 (or 19,740,785 if the option is exercised in full), based on March 31, 2026 outstanding figures.
Neurogene Inc. proposes an offering of shares of common stock and pre-funded warrants to purchase common stock, together with shares issuable upon exercise of those warrants, via a preliminary prospectus supplement dated (subject to completion). The offering will fund continued development and pre-commercial activities for NGN-401 and for working capital.
The prospectus discloses 15,615,786 shares outstanding as of March 31, 2026, historical net tangible book value of $237.8 million ($15.23 per share) and recent Nasdaq closing price of $32.28 on June 29, 2026. Key terms include tradable common stock and non-listed pre-funded warrants exercisable at $0.000001 per share with ownership limitations.
Neurogene Inc. reported updated, positive Phase 1/2 results for NGN-401, its investigational gene therapy for females with Rett syndrome. Across 10 participants, 47 developmental milestones were gained, averaging 4.7 per participant, and 100% improved on the Clinical Global Impression-Improvement scale and gained at least one milestone.
Milestones accumulated in a progressive, developmentally ordered sequence with rapid onset, as median time to first clinical improvement was two months and gains deepened by 95% from 6 to 12 months and 147% from 6 to at least 12 months. No plateau or loss of milestones was seen through up to 30 months of follow-up, and NGN-401 at the 1E15 vg dose remained generally well-tolerated, with only mild or moderate treatment-related adverse events and no new treatment-related serious adverse events. Neurogene has completed dosing of 25 participants in the Embolden registrational trial, which uses a composite responder endpoint, and expects topline data in the second half of 2027.
Neurogene Inc. director Woods Keith received a stock option grant to acquire 15,400 shares of common stock at an exercise price of $32.30 per share. The option was granted as a compensation award and vests in equal monthly installments through January 16, 2027, conditioned on continued service. Following this grant, Woods holds 15,400 stock options expiring on January 16, 2034.
Neurogene Inc. director Keith Woods received a fully vested stock option grant covering 7,700 shares of common stock. The option has an exercise price of $42.59 per share and expires on June 14, 2034. Following this award, he holds 7,700 stock options directly.
Neurogene Inc. director Keith Woods received a fully vested non-qualified stock option grant. The award covers 12,050 options, each giving the right to buy one share of common stock at an exercise price of $20.40 per share, expiring on June 12, 2035. Following this compensation-related grant, Woods holds 12,050 derivative securities directly, with no open-market share purchases or sales reported in this filing.
Neurogene Inc. director Woods Keith filed an amended Form 3, which is the initial statement of beneficial ownership for insiders. This amendment reports no share purchases, sales, option exercises, or other equity transactions, and shows no derivative securities or other holdings disclosed in this filing.